US 12,233,063 B2
Compositions and methods for treating eye disorders
Cagri Giray Besirli, Ann Arbor, MI (US); and Thomas Wubben, Ann Arbor, MI (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF MICHIGAN, Ann Arbor, MI (US)
Appl. No. 16/757,179
Filed by THE REGENTS OF THE UNIVERSITY OF MICHIGAN, Ann Arbor, MI (US)
PCT Filed Oct. 18, 2018, PCT No. PCT/US2018/056429
§ 371(c)(1), (2) Date Apr. 17, 2020,
PCT Pub. No. WO2019/079541, PCT Pub. Date Apr. 25, 2019.
Claims priority of provisional application 62/595,194, filed on Dec. 6, 2017.
Claims priority of provisional application 62/575,075, filed on Oct. 20, 2017.
Prior Publication US 2021/0196716 A1, Jul. 1, 2021
Int. Cl. A61K 31/5025 (2006.01); A61K 9/00 (2006.01); A61K 48/00 (2006.01); A61P 27/02 (2006.01); C12N 15/113 (2010.01)
CPC A61K 31/5025 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61P 27/02 (2018.01); C12N 15/1137 (2013.01); A61K 48/00 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01)] 9 Claims
 
1. A method of treating an eye disorder, comprising:
administering a composition comprising a PKM2 activator to the eye of a subject in need thereof,
wherein said administering treats or reduces symptoms of an eye disorder in said subject,
wherein said eye disorder is a retinal disease, and wherein said administering prevents or reduces photoreceptor cell death in the eye of said subject.